GO
Loading...

CNBC's Faber: Bausch & Lomb Likely to Stay With Warburg Offer

Bausch & Lomb is likely to stick to its agreement to be acquired by Warburg Pincus for $3.67 billion, or $65 per share in cash, reported CNBC's David Faber.

A Bausch & Lomb special committee, comprised of independent directors of the optical-care company, is meeting Monday to review Warburg's acquisition -- and a competing, unsolicited bid from Advanced Medical Optics for $75 per share.

The Advanced Medical Optics offer would break down into $45 per share in cash and $30 in Advanced Medical Optics stock.

"Based on communications between the two companies, it seems as though they [Bausch & Lomb] will reverse themselves" and fall back on the Warburg Pincus offer, Faber said.

"According to people familiar with the situation, they don't believe that AMO's deal is reasonably likely to be consummated -- because of AMO shareholders and the potential that they will vote against it," Faber reported.

The entire Bausch & Lomb board is slated to meet Tuesday to consider the two offers, and whether to continue talks with Advanced Medical Optics, whose offer was unsolicited.

Bausch & Lomb shares lost $1.31, or 1.94%, at $66.19 in Monday early-afternoon trading on the New York Stock Exchange.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    Please choose a subscription
    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

U.S. Video

  • Netflix nears an all-time high. Are more gains in store? With CNBC's Melissa Lee and the Options Action traders.

  • According to research from Bespoke Investment Group, less than 7 percent of all analyst ratings are to sell, with the rest fairly evenly split between buy and hold. CNBC's Jeff Cox reports.

  • The high cost of doing business in San Francisco is motivating start-ups to consider movig to Oakland where the the average asking rent is nerarly 50 percent less.